MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Ultragenyx Pharmaceutical Inc

Slēgts

SektorsVeselības aprūpe

37.57 0.97

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

36.52

Max

37.78

Galvenie mērījumi

By Trading Economics

Ienākumi

131K

-133M

Pārdošana

25M

165M

EPS

-1.39

Peļņas marža

-80.9

Darbinieki

1,294

EBITDA

-59K

-109M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+142.37% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 1. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-219M

3.3B

Iepriekšējā atvēršanas cena

36.6

Iepriekšējā slēgšanas cena

37.57

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bullish Evidence

Ultragenyx Pharmaceutical Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 24. apr. 23:54 UTC

Karstas akcijas

Stocks to Watch: Alphabet, Intel, AppFolio

2025. g. 24. apr. 23:51 UTC

Tirgus saruna

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

2025. g. 24. apr. 23:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 24. apr. 23:46 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

2025. g. 24. apr. 23:37 UTC

Top Ziņas

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

2025. g. 24. apr. 23:36 UTC

Top Ziņas

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

2025. g. 24. apr. 23:13 UTC

Top Ziņas
Peļņas

Google's Earnings Power Holds Up in Global Turbulence -- Update

2025. g. 24. apr. 23:09 UTC

Top Ziņas

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

2025. g. 24. apr. 23:02 UTC

Iegādes, apvienošanās, pārņemšana

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

2025. g. 24. apr. 23:02 UTC

Iegādes, apvienošanās, pārņemšana

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

2025. g. 24. apr. 22:51 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

2025. g. 24. apr. 22:48 UTC

Top Ziņas

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

2025. g. 24. apr. 22:47 UTC

Tirgus saruna

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

2025. g. 24. apr. 22:38 UTC

Tirgus saruna
Peļņas

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

2025. g. 24. apr. 22:24 UTC

Peļņas

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

2025. g. 24. apr. 22:24 UTC

Peļņas

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

2025. g. 24. apr. 22:24 UTC

Tirgus saruna
Peļņas

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

2025. g. 24. apr. 22:23 UTC

Peļņas

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

2025. g. 24. apr. 22:11 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 24. apr. 22:11 UTC

Tirgus saruna
Peļņas

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

2025. g. 24. apr. 22:09 UTC

Top Ziņas
Peļņas

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

2025. g. 24. apr. 22:00 UTC

Tirgus saruna
Peļņas

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

2025. g. 24. apr. 21:39 UTC

Top Ziņas

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

2025. g. 24. apr. 21:24 UTC

Top Ziņas
Peļņas

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

2025. g. 24. apr. 21:24 UTC

Top Ziņas
Peļņas

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

2025. g. 24. apr. 21:23 UTC

Top Ziņas
Peļņas

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

2025. g. 24. apr. 21:04 UTC

Peļņas

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

2025. g. 24. apr. 21:03 UTC

Peļņas

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

2025. g. 24. apr. 21:03 UTC

Peļņas

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

2025. g. 24. apr. 21:02 UTC

Peļņas

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Salīdzinājums

Cenas izmaiņa

Ultragenyx Pharmaceutical Inc Prognoze

Cenas mērķis

By TipRanks

142.37% augšup

Prognoze 12 mēnešiem

Vidējais 90.43 USD  142.37%

Augstākais 136 USD

Zemākais 39 USD

Pamatojoties uz 16 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ultragenyx Pharmaceutical Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

16 ratings

15

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

35.34 / N/AAtbalsts un pretestība

Īstermiņā

Very Strong Bullish Evidence

Vidējā termiņā

Neutral Evidence

Ilgtermiņā

Weak Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.